Literature DB >> 19726225

Evidence of inability of human cytomegalovirus to reactivate Kaposi's sarcoma-associated herpesvirus from latency in body cavity-based lymphocytes.

Bo Cheng1, Francisco Puerta Martínez, Harutaka Katano, Qiyi Tang.   

Abstract

BACKGROUND: Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8 (HHV-8)) has been determined to be the most frequent cause of malignancies in AIDS patients. It is associated primarily with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), as well as with multicentric Castleman's disease (MCD).(2) The switch from the latent to the lytic stage is important in the maintenance of malignancy and viral infection. So far, the mechanism of its reactivation has not been fully understood.
OBJECTIVES: Human cytomegalovirus (HCMV) and KSHV might infect the same cells, and it was found by other groups that several viruses could reactivate KSHV from latency. We investigate whether HCMV infection could reactivate KSHV from latency in body cavity-based lymphocyte (BCBL-1) cells. STUDY DESIGN AND
RESULTS: Laboratory strains of HCMV cannot infect B cells. In this article, we demonstrate that the UL131-repaired HCMV (vDW215-BADrUL131) derived from AD169 strain is able to infect B lymphocytes. We directly infected KSHV latent cells including BCBL-1 with vDW215-BADrUL131 to evaluate the ability of HCMV to reactivate KSHV. Inconsistent with previous reports in human fibroblast cells, our results provide direct evidence that HCMV is unable to reactivate KSHV from latency-to-lytic infection in BCBL-1 cell lines. As a control, herpes simplex virus type 1 (HSV-1) was shown to be able to reactivate KSHV.
CONCLUSIONS: Our observations, different from others, suggest that reactivation mechanisms for KSHV might vary in different cells.

Entities:  

Mesh:

Year:  2009        PMID: 19726225      PMCID: PMC2789304          DOI: 10.1016/j.jcv.2009.07.025

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  32 in total

1.  Coding potential of laboratory and clinical strains of human cytomegalovirus.

Authors:  Eain Murphy; Dong Yu; Jane Grimwood; Jeremy Schmutz; Mark Dickson; Michael A Jarvis; Gabriele Hahn; Jay A Nelson; Richard M Myers; Thomas E Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

2.  The human cytomegalovirus UL112-113 locus can activate the full Kaposi's sarcoma-associated herpesvirus lytic replication cycle.

Authors:  Richard Wells; Laurence Stensland; Jeffrey Vieira
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

3.  Prevalence of blood-borne viral infections (cytomegalovirus, human herpesvirus-6, human herpesvirus-7, human herpesvirus-8, human T-cell lymphotropic virus-I/II, human retrovirus-5) among blood donors in Latvia.

Authors:  S Kozireva; G Nemceva; I Danilane; O Pavlova; J Blomberg; M Murovska
Journal:  Ann Hematol       Date:  2001-11       Impact factor: 3.673

4.  Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus.

Authors:  J Vieira; P O'Hearn; L Kimball; B Chandran; L Corey
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Herpesvirus type 1-8 in BAL fluid from HIV-1-infected patients with suspected pneumonia and from healthy individuals.

Authors:  B Tarp; S Jensen-Fangel; R Dahl; N Obel
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

6.  Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes.

Authors:  Gabriele Hahn; Maria Grazia Revello; Marco Patrone; Elena Percivalle; Giulia Campanini; Antonella Sarasini; Markus Wagner; Andrea Gallina; Gabriele Milanesi; Ulrich Koszinowski; Fausto Baldanti; Giuseppe Gerna
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

8.  Two novel spliced genes in human cytomegalovirus.

Authors:  Parvis Akter; Charles Cunningham; Brian P McSharry; Aidan Dolan; Clare Addison; Derrick J Dargan; Aycan F Hassan-Walker; Vincent C Emery; Paul D Griffiths; Gavin W G Wilkinson; Andrew J Davison
Journal:  J Gen Virol       Date:  2003-05       Impact factor: 3.891

9.  Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression.

Authors:  Harinivas H Krishnan; Pramod P Naranatt; Marilyn S Smith; Ling Zeng; Clark Bloomer; Bala Chandran
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Mouse cytomegalovirus immediate-early protein 1 binds with host cell repressors to relieve suppressive effects on viral transcription and replication during lytic infection.

Authors:  Qiyi Tang; Gerd G Maul
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  3 in total

1.  Sirtuin 6 Attenuates Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Suppressing Ori-Lyt Activity and Expression of RTA.

Authors:  Min Hu; Najealicka Armstrong; Edward Seto; Wenwei Li; Fanxiu Zhu; Paul C Wang; Qiyi Tang
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

2.  Cellular microRNAs 498 and 320d regulate herpes simplex virus 1 induction of Kaposi's sarcoma-associated herpesvirus lytic replication by targeting RTA.

Authors:  Qin Yan; Wan Li; Qiao Tang; Shuihong Yao; Zhigang Lv; Ninghan Feng; Xinting Ma; Zhiqiang Bai; Yi Zeng; Di Qin; Chun Lu
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

3.  Functional interaction of nuclear domain 10 and its components with cytomegalovirus after infections: cross-species host cells versus native cells.

Authors:  Ruth Cruz Cosme; Francisco Puerta Martínez; Qiyi Tang
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.